~~<i id='39A5889F6B'><strike id='39A5889F6B'><tt id='39A5889F6B'><pre id='39A5889F6B'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

focus

author：explore 2025-09-06 02:06:05 - browse：9

In a dark grey suit and light blue button-down shirt, Bill Sibold, CEO of Madrigal Pharmaceuticals, smiles— coverage from STAT — Madrigal CEO Bill Sibold says the company is "interested in the patients who are most in need." Madrigal Pharmaceuticals

The Food and Drug Administration is expected to approve the first medicine developed specifically to treat the serious liver disease known as MASH as soon as this week.

The pill, called resmetirom, is made by Madrigal Pharmaceuticals.

Metabolic dysfunction-associated steatohepatitis, or MASH and previously called NASH, is often associated with obesity. The accumulation of fat in the liver causes inflammation, which leads to fibrosis, or liver scarring, and can progress in more advanced stages to cirrhosis, cancer, and the need for a liver transplant.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Group opposing PBM reform sets lobbying record

focus

knowledge

focus

hotspot

2:14PresidentDonaldTrumpspeakstosupportersfromTheEllipseneartheWhiteHouseonJanuary6,2021,inWashingto

WSS

Medicare to cover more brain scans for Alzheimer’s patients

Custom gene therapy hints at new path for rare disease treatments

Presidential candidate assassinated in Ecuador, 1 suspect dead and 6 arrested

Novo acquires Inversago for up to $1 billion

Covid's long

Where are patients getting their prescriptions for GLP

leisure time

focus

focus

How one medical school became remarkably diverse

Cosmetics set for new safety regulation. Why the industry is on board

Trump demands the U.S. pay no more for drugs than other countries … again

Target recalls 2.2 million additional candles due to laceration, burn hazards

Moonlake's readout produced a cash windfall. Risks remain

Listen: Your guide to Wegovy's blockbuster heart study

Peter Hotez and the public health issue of online harassment

Large hospital system sues Multiplan for low

Novavax promises a turnaround & Lilly roils the obesity market

A public scorecard can help hold safety

knowledge

Why hospitals are withdrawing from US News rankings

Maui funeral service workers on devastation of fires: 'I'm in shock'

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

How dance can help nurses traumatized by Covid

FDA approves RSV monoclonal antibody for infants, toddlers

FDA approves RSV monoclonal antibody for infants, toddlers

knowledge

focus

focus

hotspot